OncoSynergy is a clinical stage immuno-oncology therapeutics company pioneering a breakthrough approach to significantly improving outcomes for patients suffering from the worst cancers.
Our transformational approach to fighting cancer involves targeting central cancer drivers/multiple cancer hallmarks simultaneously (vs most modern approaches targeting single cancer hallmarks). Our lead program OS2966, a first-in-class anti-CD29 (Beta 1 integrin) monoclonal antibody, is advancing to phase 1 clinical trials in recurrent glioblastoma 2H 2020 and is FDA Orphan Drug Designated in the treatment of both glioblastoma and ovarian cancer. OS2966 has also demonstrated in vivo proof of concept in the treatment of triple-negative breast cancer, malignant meningioma, pancreatic cancer, and acute leukemias.
Additionally, we have evidenced significant synergy with other immunotherapies, radiation, and chemotherapy in both solid and hematological malignancies.
Our transformational approach to fighting cancer involves targeting central cancer drivers/multiple cancer hallmarks simultaneously (vs most modern approaches targeting single cancer hallmarks). Our lead program OS2966, a first-in-class anti-CD29 (Beta 1 integrin) monoclonal antibody, is advancing to phase 1 clinical trials in recurrent glioblastoma 2H 2020 and is FDA Orphan Drug Designated in the treatment of both glioblastoma and ovarian cancer. OS2966 has also demonstrated in vivo proof of concept in the treatment of triple-negative breast cancer, malignant meningioma, pancreatic cancer, and acute leukemias.
Additionally, we have evidenced significant synergy with other immunotherapies, radiation, and chemotherapy in both solid and hematological malignancies.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Oncology
Lead Product in Development:
OS2966
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
